Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Haemophilia ; 24(5): e354-e362, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30024643

ABSTRACT

INTRODUCTION: B-domain modification can improve production of recombinant factor VIII (rFVIII) proteins. However, the engineered junction results in non-native peptide sequences with the potential to elicit immune responses via major histocompatibility complex class-II (MHC-II)-binding and CD4+ T cell activation. AIM: Assess the immunogenic potential of B-domain junction peptides of turoctocog alfa and other B-domain-modified rFVIII proteins using in silico and in vitro immunogenicity assessment techniques. METHODS: Peptides with amino acid sequences identical to the B-domain junction of turoctocog alfa, simoctocog alfa and moroctocog alfa were evaluated by in silico peptide-MHC-II binding prediction, in vitro peptide-MHC-II-binding measurement and in vitro T cell-activation assays. Moreover, turoctocog alfa was assessed for peptide presentation on dendritic cells (DCs) using MHC-associated peptide proteomics. RESULTS: In silico analysis predicted virtually no neo-epitopes in the B-domain junction for turoctocog alfa, whereas some were predicted for simoctocog alfa and moroctocog alfa. Turoctocog alfa and moroctocog alfa peptides showed minimal capacity to bind high-frequency MHC-II molecules in vitro, whereas simoctocog alfa peptide demonstrated some degree of binding to approximately half of the MHC-II molecules tested. In line with this, no B-domain peptides from turoctocog alfa were found to be presented on MHC-II complexes on DCs. B-domain junction peptides from all 3 compounds induced T cell responses in only a few percentages of donors. CONCLUSION: All 3 junction peptides were found to have a low immunogenicity potential, suggesting that modification of the B-domain does not constitute an increased immunogenicity risk for any of the products examined.


Subject(s)
Computer Simulation , Factor VIII/metabolism , Hemophilia A/genetics , Histocompatibility Antigens Class II/metabolism , Animals , Disease Models, Animal , Hemophilia A/metabolism , Humans , Mice
2.
Internist (Berl) ; 56(2): 189-90, 192-4, 2015 Feb.
Article in German | MEDLINE | ID: mdl-25617003

ABSTRACT

Snake bites are rare events in Germany and are not life-threatening with usually only mild clinical symptoms. The most widespread venomous snake is the common European adder (Vipera berus). Here we present the case of a 53-year-old woman who was bitten by a common adder. Although the patient was initially in stable condition she developed edematous swelling of the complete lower limb, subcutaneous bleeding, and rhabdomyolysis. The aim of this report is to raise awareness that even in a central European country like Germany snake bites with a life-threatening course can occur and need immediate attention and medical care.


Subject(s)
Antivenins/therapeutic use , Edema/diagnosis , Snake Bites/diagnosis , Snake Bites/therapy , Travel , Viperidae , Animals , Diagnosis, Differential , Edema/etiology , Edema/prevention & control , Female , Humans , Middle Aged , Snake Bites/complications , Treatment Outcome
3.
Pathologe ; 34(4): 335-7, 2013 Jul.
Article in German | MEDLINE | ID: mdl-23436120

ABSTRACT

Maxillary ameloblastomas can extensively expand into the paranasal sinuses or even the nasal cavity due to a slow growth pattern. Sinusitis is rarely the first tumor-related complaint. Due to the various growth forms of ameloblastomas the challenging histological differential diagnosis includes several other odontogenic as well as benign and malignant non-odontogenic tumors, e.g. tumors from the mucosa of the paranasal sinuses, salivary glands and Rathke's pouch. Despite the radical surgical approach a complete resection with wide margins cannot always be achieved. Maxillary ameloblastomas show the highest recurrence rates.


Subject(s)
Ameloblastoma/pathology , Ethmoid Sinus/pathology , Maxillary Neoplasms/pathology , Maxillary Sinus Neoplasms/pathology , Nose Neoplasms/pathology , Paranasal Sinus Neoplasms/pathology , Adult , Ameloblastoma/surgery , Endoscopy , Ethmoid Sinus/surgery , Follow-Up Studies , Humans , Male , Maxilla/pathology , Maxilla/surgery , Maxillary Neoplasms/surgery , Maxillary Sinus Neoplasms/surgery , Nasal Cavity/pathology , Neoplasm Invasiveness , Nose Neoplasms/surgery , Olfaction Disorders/etiology , Paranasal Sinus Neoplasms/surgery , Radiography, Panoramic , Sinusitis/etiology , Sinusitis/surgery , Tomography, X-Ray Computed
4.
J Cell Biol ; 129(2): 299-308, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7721935

ABSTRACT

The key enzyme of chlorophyll biosynthesis in higher plants, the light-dependent NADPH:protochlorophyllide oxidoreductase (POR, EC 1.6.99.1), is a nuclear-encoded plastid protein. Its posttranslational transport into plastids of barley depends on the intraplastidic availability of one of its substrates, protochlorophyllide (PChlide). The precursor of POR (pPOR), synthesized from a corresponding full-length barley cDNA clone by coupling in vitro transcription and translation, is enzymatically active and converts PChlide to chlorophyllide (Chlide) in a light- and NADPH-dependent manner. Chlorophyllide formed catalytically remains tightly but noncovalently bound to the precursor protein and stabilizes a transport-incompetent conformation of pPOR. As shown by in vitro processing experiments, the chloroplast transit peptide in the Chlide-pPOR complex appears to be masked and thus is unable to physically interact with the outer plastid envelope membrane. In contrast, the chloroplast transit peptide in the naked pPOR (without its substrates and its product attached to it) and in the pPOR-substrate complexes, such as pPOR-PChlide or pPOR-PChlide-NADPH, seems to react independently of the mature region of the polypeptide, and thus is able to bind to the plastid envelope. When envelope-bound pPOR-PChlide-NADPH complexes were exposed to light during a short preincubation, the enzymatically produced Chlide slowed down the actual translocation step, giving rise to the sequential appearance of two partially processed translocation intermediates. However, ongoing translocation induced by feeding the chloroplasts delta-aminolevulinic acid, a precursor of PChlide, was able to override these two early blocks in translocation, suggesting that the plastid import machinery has a substantial capacity to denature a tightly folded, envelope-bound precursor protein. Together, our results show that pPOR with Chlide attached to it is impaired both in the ATP-dependent step of binding to a receptor protein component of the outer chloroplast envelope membrane, as well as in the PChlide-dependent step of precursor translocation.


Subject(s)
Chlorophyllides/metabolism , Chloroplasts/metabolism , Oxidoreductases Acting on CH-CH Group Donors , Oxidoreductases/metabolism , Protein Precursors/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Biological Transport, Active/drug effects , Cell Membrane/metabolism , Chlorophyllides/pharmacology , Hordeum/enzymology , Light , Oxidoreductases/chemistry , Protein Folding , Protein Precursors/chemistry , Protein Sorting Signals/physiology , Protochlorophyllide/metabolism
5.
Diabetes Obes Metab ; 10(1): 91-3, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18095950

ABSTRACT

AIM: We suspect that the life-threatening complication of metformin-associated lactic acidosis, solely due to drug accumulation following renal impairment, occurs more frequently than that previously reported and is not necessarily associated with other predisposing factors for lactic acidosis. METHODS: During a period of 13 months, at a tertiary referral centre, the incidence of lactic acidosis of any aetiology was 12.8% [67 of 524 total intensive care unit (ICU) admissions]. Metformin-associated lactic acidosis solely as the result of drug accumulation was diagnosed in 6% of all the patients suffering from lactic acidosis (4 of 67 patients). RESULTS: These patients presented with severe circulatory shock due to lactic acidosis. We could not identify any predisposing factor for lactic acidosis other than renal impairment. Intercurrent deterioration of diabetic nephropathy was suspected to be responsible for the accumulation of metformin followed by lactic acidosis, finally resulting in multiorgan failure. The diagnosis was supported by extensively elevated serum levels of metformin. Two patients died during ICU treatment. CONCLUSIONS: Our data indicate that the incidence of metformin-associated lactic acidosis solely due to metformin accumulation is possible and underestimated. Symptoms of metformin-associated lactic acidosis are unspecific and physicians should be aware that metformin, if prescribed in patients with renal impairment, can cause fatal lactic acidosis due to drug accumulation.


Subject(s)
Acidosis, Lactic/chemically induced , Diabetic Nephropathies/complications , Hypoglycemic Agents/adverse effects , Metformin/adverse effects , Renal Insufficiency/complications , Aged , Female , Humans , Hypoglycemic Agents/pharmacokinetics , Male , Metformin/pharmacokinetics , Middle Aged
6.
Eur J Pharm Biopharm ; 68(3): 535-44, 2008 Mar.
Article in English | MEDLINE | ID: mdl-17804210

ABSTRACT

Solid lipid nanoparticles (SLN) were produced loaded with cyclosporine A in order to develop an improved oral formulation. In this study, the particles were characterized with regard to the structure of the lipid particle matrix, being a determining factor for mode of drug incorporation and drug release. Differential scanning calorimetry (DSC) and wide-angle X-ray scattering (WAXS) measurements were employed for the analysis of the polymorphic modifications and mode of drug incorporation. Particles were produced using Imwitor 900 as lipid matrix (the suspension consisted of 10% particles, 8% Imwitor 900, 2% cyclosporine A), 2.5% Tagat S, 0.5% sodium cholate and 87% water. DSC and WAXS were used to analyse bulk lipid, bulk drug, drug incorporated in the bulk and unloaded and drug-loaded SLN dispersions. The processing of the bulk lipid into nanoparticles was accompanied by a polymorphic transformation from the beta to the alpha-modification. After production, the drug-free SLN dispersions converted back to beta-modification, while the drug-loaded SLN stayed primarily in alpha-modification. After incorporation of cyclosporine A into SLN, the peptide lost its crystalline character. Based on WAXS data, it could be concluded that cyclosporine is molecularly dispersed in between the fatty acid chains of the liquid-crystalline alpha-modification fraction of the loaded SLN.


Subject(s)
Cyclosporine/administration & dosage , Lipids/administration & dosage , Nanoparticles/administration & dosage , Calorimetry, Differential Scanning , Cyclosporine/chemistry , Drug Carriers , Scattering, Radiation , X-Rays
8.
Int J Pharm ; 317(1): 82-9, 2006 Jul 06.
Article in English | MEDLINE | ID: mdl-16580159

ABSTRACT

For the development of an optimized oral formulation for cyclosporine A, 2% of this drug has been formulated in solid lipid nanoparticles (SLN, mean size 157 nm) and as nanocrystals (mean size 962 nm). The encapsulation rate of SLN was found to be 96.1%. Nanocrystals are composed of 100% of drug. For the assessment of the pharmacokinetic parameters the developed formulations have been administered via oral route to three young pigs. Comparison studies with a commercial Sandimmun Neoral/Optoral used as reference have been performed. The blood profiles observed after oral administration of the commercial microemulsion Sandimmun revealed a fast absorption of drug leading to the observation of a plasma peak above 1,000 ng/ml within the first 2 h. For drug nanocrystals most of the blood concentrations were in the range between 30 and 70 ng/ml over a period of 14 h. These values were very low, showing huge differences between the measuring time points and between the tested animals. On the contrary, administration of cyclosporine-loaded SLN led to a mean plasma profile with almost similarly low variations in comparison to the reference microemulsion, however with no initial blood peak as observed with the Sandimmun Neoral/Optoral. Comparing the area under the curves (AUC) obtained with the tested animals it could be stated that the SLN formulation avoids side effects by lacking blood concentrations higher than 1,000 ng/ml. In this study it has been proved that using SLN as a drug carrier for oral administration of cyclosporine A a low variation in bioavailability of the drug and simultaneously avoiding the plasma peak typical of the first Sandimmun formulation can be achieved.


Subject(s)
Cyclosporine/administration & dosage , Drug Delivery Systems , Nanoparticles , Administration, Oral , Animals , Biological Availability , Crystallization , Cyclosporine/blood , Cyclosporine/pharmacokinetics , Intestinal Absorption , Particle Size , Swine
9.
Biotechniques ; 12(5): 630-1, 1992 May.
Article in English | MEDLINE | ID: mdl-1387539

ABSTRACT

Current methods of analyzing fusion proteins from lambda gt11 clones involve either subcloning of the insert DNA into a plasmid expression vector or production of lambda gt11 lysogens that are subsequently induced. Both of these methods can be quite time-consuming. The present communication describes a novel strategy for induction of the fusion protein that is both simple and rapid. Liquid cultures of E. coli Y1090R- infected with the lambda gt11 clone were induced directly to produce the fusion protein. Following the preparation of a crude bacterial cell lysate, fusion products were subjected to Western blot analysis.


Subject(s)
Bacteriophage lambda/genetics , Cloning, Molecular/methods , Lysogeny/genetics , Viral Fusion Proteins/analysis , Animals , Blotting, Western , Rats , Tumor Cells, Cultured , Viral Fusion Proteins/genetics
10.
Br J Pharmacol ; 138(5): 787-94, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12642379

ABSTRACT

(1) Glucagon and glucagon-like peptide-1 (GLP-1) are homologous peptide hormones with important functions in glucose metabolism. The receptors for glucagon and GLP-1 are homologous family B G-protein coupled receptors. The GLP-1 receptor amino-terminal extracellular domain is a major determinant of glucagon/GLP-1 selectivity of the GLP-1 receptor. However, the divergent residues in glucagon and GLP-1 that determine specificity for the GLP-1 receptor amino-terminal extracellular domain are not known. Less is known about how the glucagon receptor distinguishes between glucagon and GLP-1. (2) We analysed chimeric glucagon/GLP-1 peptides for their ability to bind and activate the glucagon receptor, the GLP-1 receptor and chimeric glucagon/GLP-1 receptors. The chimeric peptide GLP-1(7-20)/glucagon(15-29) was unable to bind and activate the glucagon receptor. Substituting the glucagon receptor core domain with the GLP-1 receptor core domain (chimera A) completely rescued the affinity and potency of GLP-1(7-20)/glucagon(15-29) without compromising the affinity and potency of glucagon. Substituting transmembrane segment 1 (TM1), TM6, TM7, the third extracellular loop and the intracellular carboxy-terminus of chimera A with the corresponding glucagon receptor segments re-established the ability to distinguish GLP-1(7-20)/glucagon(15-29) from glucagon. Corroborant results were obtained with the opposite chimeric peptide glucagon(1-14)/GLP-1(21-37). (3) The results suggest that the glucagon and GLP-1 receptor amino-terminal extracellular domains determine specificity for the divergent residues in the glucagon and GLP-1 carboxy-terminals respectively. The GLP-1 receptor core domain is not a critical determinant of glucagon/GLP-1 selectivity. Conversely, the glucagon receptor core domain contains two or more sub-segments which strongly determine specificity for divergent residues in the glucagon amino-terminus.


Subject(s)
Receptors, Glucagon/chemistry , Receptors, Glucagon/metabolism , Amino Acid Sequence , Binding, Competitive/genetics , Binding, Competitive/physiology , Cell Line , Dose-Response Relationship, Drug , Glucagon-Like Peptide-1 Receptor , Humans , Ligands , Molecular Sequence Data , Protein Binding/genetics , Protein Binding/physiology , Protein Structure, Tertiary , Receptors, Glucagon/genetics , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/metabolism
11.
Leuk Res ; 15(6): 427-33, 1991.
Article in English | MEDLINE | ID: mdl-1861529

ABSTRACT

A unique oncofetal protein (OFP) previously identified in rat fetal tissue and rat and human solid tumors, is now shown to be present in rat and human leukemia cells by use of a monoclonal antibody-based assay. Using a highly specific anti-rat OFP monoclonal antibody OFP has been unquivocally immunolocalized to the cytoplasm of the rat leukemia cells. The factor is rapidly released to the circulation as 50 and 55 kD species which share the immunological determinants. When leukemia cells are transplanted to normal rats, OFP increases in the circulation in a biphasic manner which may be due to immune clearance since circulating anti-OFP antibodies have been demonstrated. Induction of differentiation in the human HL-60 leukemia cell line by 13-cis-retinoic acid caused a down regulation of OFP synthesis, both intra- and extra-cellular levels dropping to essentially zero. Induction of differentiation with dibutyryl cyclic AMP caused a cessation of secretion of OFP, with a marked increase in its intracellular concentration, a condition resembling the retention in fetal cells. Leukemia cells add to a growing list of tumors previously shown to produce OFP, suggesting that OFP is intimately involved in some facet of tumorigenesis.


Subject(s)
Antigens, Neoplasm/genetics , Leukemia, Experimental/genetics , Leukemia, Myeloid/genetics , Animals , Antigens, Neoplasm/blood , Antigens, Neoplasm/metabolism , Cell Differentiation/drug effects , Down-Regulation/physiology , Fluorescent Antibody Technique , Gene Expression Regulation, Leukemic/physiology , Humans , Leukemia, Experimental/metabolism , Leukemia, Experimental/pathology , Leukemia, Myeloid/metabolism , Leukemia, Myeloid/pathology , Molecular Weight , Neoplasm Transplantation , Rats , Rats, Inbred F344 , Tretinoin/pharmacology , Tumor Cells, Cultured
12.
Methods Mol Med ; 51: 223-33, 2001.
Article in English | MEDLINE | ID: mdl-21331719

ABSTRACT

In situ hybridization (ISH) is employed principally to detect mRNA within cells and tissues. ISH begins with the synthesis of a nucleic acid probe complementary in sequence to a cellular target. Through incorporation of a radioactive nucleotide into the probe, a cellular target may be visualized using autoradiography. A nonradioactive variation of this technique utilizing digoxigenin has been championed by some researchers, but our experience has been that radioactive probes produce more reliable and accurate results. Although not a difficult technique, ISH incorporates many steps, which must be performed with care and precision to obtain useful results.

14.
Growth Horm IGF Res ; 21(3): 181-4, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21658594

ABSTRACT

BACKGROUND: Primary intracranial germ cell tumors usually present in the first two decades of life, often with precocious puberty. The most common location is in the pineal gland; suprasellar germ cell tumors are rare. We present an additional case of a suprasellar choriocarcinoma producing GH, and review the literature. CASE: This French Canadian, 17 year-old male presented to the ER with a history of mild weight loss and an episode of syncope while hiking in Mexico, but with no other neurological symptoms. Puberty began at age 13 years (growth spurt: 15-16 years), and he attained an adult height within genetic target by age 16 years. Past medical history was negative except for myopia diagnosed during childhood. System review revealed increased thirst and nocturia. The mother was treated for an oligo-astrocytoma in 2007. Clinical examination showed a euthyroid, well-looking young man with 20 ml testicles. Endocrine evaluation revealed elevated testosterone, mildly elevated PRL, borderline low FT4, and decreased IGF-I, morning cortisol and urine osmolality; tumor markers were positive in serum and CSF (hCG>50 IU/L, AFP>10 ng/mL). A transphenoidal biopsy of a 4.5 cm, homogeneous, non-calcified, suprasellar mass was compatible with the diagnosis of choriocarcinoma and stained intensely for hCG and hGH, presumably the placental variant (GH-V) as previously found in vitro in choriocarcinoma cell lines. Combined chemotherapy and irradiation led to tumor regression and undetectable serum hCG to 36 months of follow-up. He is doing well with no evidence of tumor progression and is on complete hormone replacement therapy. CONCLUSIONS: Choriocarcinomas can have a hormonal profile that delays the development of symptoms, due to hCG stimulation of both the gonadal and thyroid axes. This report corroborates previous in vitro evidence that choriocarcinoma cells are able to make GH-V. To what extent the patient's tumor-derived GH contributed to his normal growth is not known. Prognosis for this intracranial neoplasm is very reserved, although combined radiotherapy and chemotherapy has been successful in our patient now 36 months post-diagnosis.


Subject(s)
Choriocarcinoma/diagnosis , Chorionic Gonadotropin/analysis , Growth Hormone/analysis , Pituitary Neoplasms/diagnosis , Adolescent , Choriocarcinoma/pathology , Humans , Immunohistochemistry , Male , Pituitary Neoplasms/pathology
16.
Dtsch Med Wochenschr ; 133(49): 2572-8, 2008 Dec.
Article in German | MEDLINE | ID: mdl-19039713

ABSTRACT

Atrial fibrillation is the most frequent cardiac arrthythmia in adults and its prevalence is increasing with age. Therefore, the importance of an adequate therapy is an increasing challenge, in particular considering the demographic shift towards an aging population. Current antiarrhythmic drug therapies for the conversion of atrial fibrillation and the maintenance of sinus rhythm are limited by efficacy, tolerance and safety of the currently available agents. Therefore, a primary goal is to develop effective antiarrhythmic drugs with as little as possible side effects. The following review describes new promising drug therapy approaches to atrial fibrillation that may overcome some of the limitations of current therapies.


Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Atrial Fibrillation/drug therapy , Action Potentials , Age Factors , Amiodarone/therapeutic use , Anti-Arrhythmia Agents/adverse effects , Atrial Fibrillation/physiopathology , Heart Atria/drug effects , Humans , Ion Channels/physiology
17.
Horm Metab Res ; 40(7): 491-7, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18401838

ABSTRACT

Risk determinants for the life threatening complication of metformin-associated lactic acidosis are frequently disregarded. Our first aim was to investigate the prevalence of risk determinants in subjects with type 2 diabetes mellitus (DM2) taking metformin compared to subjects with nonmetformin treatment. Our second aim was to estimate the proportion of subjects with alternative drug-treatment, and no risk determinants, which would probably benefit from metformin. The Study of Health in Pomerania is a population-based health survey including 322 DM2 subjects. Risk determinants were assessed by personal interview, ultrasound, and laboratory analysis. Among the subjects with DM2 n=92 (28.6%) were treated with metformin, n=162 (50.3%) with alternative medication, and n=68 (21.1%) with diet. The prevalence of at least one risk determinant was 65% [corrected] for metformin-users. There was no difference in number and type of risk determinants. Heart failure, angina pectoris, and liver disorders presented the most frequent risk determinants. Current risk determinants for metformin-associated lactic acidosis are largely disregarded. Improved selection of patients can result in safe metformin utilization in one quarter of subjects on DM2 related drug treatment. Risk determinants need to be revised. A more practical definition of risk determinants would improve prescription adherence.


Subject(s)
Acidosis, Lactic/chemically induced , Acidosis, Lactic/epidemiology , Diabetes Mellitus, Type 2/drug therapy , Metformin/adverse effects , Metformin/therapeutic use , Acidosis, Lactic/etiology , Adult , Aged , Algorithms , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/epidemiology , Female , Germany/epidemiology , Health , Humans , Hypoglycemic Agents/adverse effects , Hypoglycemic Agents/therapeutic use , Male , Middle Aged , Patient Selection , Prevalence , Risk Factors
18.
J Comp Physiol B ; 174(2): 129-38, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14648099

ABSTRACT

We used the Aplysia californica intestinal epithelium to investigate the effect of alanine-stimulated Na+ absorption on apical membrane exocytosis and whether stimulated exocytosis requires intact actin filaments. The fluid-phase marker fluorescein dextran was used to determine rates of apical membrane exocytosis. L-alanine significantly increased apical exocytosis by approximately 30% compared to controls, and there is a modest, positive correlation between alanine-stimulated exocytosis and short-circuit current (ISC). Thus, apical exocytosis is modulated to some extent by the magnitude of Na+ and alanine entry across the apical membrane. Apical exocytosis is also responsive to virtually any increase in Na+ and alanine entry because increments in alanine-stimulated ISC as small as 1 microA/cm2 stimulated exocytosis. We used D-alanine to determine which parameter (sensitivity to transport vs. magnitude of transport) was most important in activation of apical exocytosis. D-alanine-stimulated ISC was one-sixth that of L-alanine, but stimulated exocytosis was only 29% less than that of L-alanine. Therefore, the apical exocytic system is more responsive to small increases in transport than to the magnitude of transport. Latrunculin A (Lat-A) disrupts the actin cytoskeleton and reduced constitutive apical exocytosis by approximately 65% and completely abolished alanine-stimulated exocytosis. Hence, constitutive exocytosis and alanine-stimulated exocytosis require actin filaments for recruitment of vesicles to the apical membrane. During nutrient absorption, actin filament-regulated apical exocytosis may represent a negative feedback system that modulates apical membrane tension.


Subject(s)
Alanine/pharmacology , Aplysia/physiology , Enterocytes/drug effects , Enterocytes/physiology , Actins/metabolism , Animals , Dextrans , Exocytosis/drug effects , Fluoresceins , Fluorescent Dyes , Ion Transport/drug effects , Sodium/metabolism
19.
Anesth Analg ; 67(11): 1032-5, 1988 Nov.
Article in English | MEDLINE | ID: mdl-2847594

ABSTRACT

The effect of halothane concentration on the binding of the calcium antagonist, [3H] nitrendipine (3HNTP), to rat and rabbit heart membranes was examined in vitro because it has been hypothesized that one mechanism by which halothane depresses cardiac contractility is by interfering with Ca2+ channel function. Membranes were incubated for 90 minutes in a closed system with 3HNTP and increasing concentrations of halothane. The amount of 3HNTP bound to membranes was quantified by radioligand binding technique and liquid scintillation counting. It was found in both the rat and rabbit cardiac membranes that halothane (0.4-2.0%) caused a dose-dependent decrease in specific 3HNTP binding (P less than 0.0001). The decrease in 3HNTP binding caused by halothane was also found to be reversible. These results indicate that halothane interferes with one property of the Ca2+ channel and suggest that this may be one possible mechanism for the negative inotropic action of halothane.


Subject(s)
Calcium Channels/drug effects , Halothane/pharmacology , Myocardium/metabolism , Nitrendipine/metabolism , Receptors, Nicotinic/drug effects , Animals , Calcium Channels/metabolism , Heart/drug effects , In Vitro Techniques , Rabbits , Radioligand Assay , Rats , Rats, Inbred Strains , Receptors, Nicotinic/metabolism
20.
Immunol Invest ; 20(3): 269-86, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1874559

ABSTRACT

An oncofetal protein (OFP) studied in our laboratory associated with embryogenesis, carcinogenesis and tumorigenesis has as its known biological function the modification of RNA release from isolated nuclei. In the present study, we have developed and investigated the use of monoclonal antibodies against OFP. Six hybridoma cell lines (A-F) were isolated by screening the hybridoma culture media for anti-OFP antibodies (MOFP) with an indirect ELISA and by testing the ability of these antibodies complexed with anti-mouse IgG-agarose to bind to rat OFP and remove its associated RNA transport activity from solution (Immunobioassay). An inhibition ELISA developed to measure OFP gave a linear response up to 20 ng of plasma protein from a tumor-bearing rat. Western blot analysis using these monoclonals showed that OFP from a rat tumor (H7777) cytosol that shed to the blood consisted of two species exhibiting molecular weights of 50 and 55 kD respectively. In order to show the usefulness of our assays, a preliminary study showing the ability of the immunobioassay to detect the expression of OFP in the plasma of carcinogen treated rats in a dosage dependent manner has been presented. Since OFP is produced in the target organ of rats shortly after treatment with carcinogens and persists in the preneoplastic foci and subsequent tumors, these monoclonal antibodies will be valuable in studying its involvement in chemical carcinogenesis and tumorigenesis.


Subject(s)
Antibodies, Monoclonal/immunology , Antigens, Neoplasm/immunology , Biomarkers, Tumor/analysis , Animals , Antibodies, Monoclonal/isolation & purification , Antigens, Neoplasm/analysis , Blotting, Western , Diethylnitrosamine , Enzyme-Linked Immunosorbent Assay , Liver Neoplasms, Experimental/blood , Liver Neoplasms, Experimental/chemically induced , Liver Neoplasms, Experimental/chemistry , RNA, Messenger/metabolism , RNA, Neoplasm/metabolism , Rats , Rats, Inbred BUF
SELECTION OF CITATIONS
SEARCH DETAIL